Last reviewed 2026-04-23 · How we verify

KRN321

Kyowa Kirin Co., Ltd. · Phase 2 active Small molecule

At a glance

Generic name	KRN321
Sponsor	Kyowa Kirin Co., Ltd.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Luspatercept + Darbepoetin in MDS (PHASE2)
Vafseo Outcomes In-Center Experience (PHASE3)
Choices About Genetic Testing And Learning Your Risk With Smart Technology (NA)
Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants (PHASE2)
Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan (PHASE3)
Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan (PHASE3)
A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD) (PHASE3)
Darbepoetin in Patients Candidates for Liver Transplant. (EPO-LT Trial) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results